Spinal cord injury causes chronic liver pathology in rats

Journal of Neurotrauma

Volumn 32, Issue 3, 2015, Pages 159-169

  Sauerbeck, Andrew D ^a   Laws, J Lukas ^a   Bandaru, Veera V R ^b   Popovich, Phillip G ^a   Haughey, Norman J ^b   McTigue, Dana M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute phase response; cytokines; metabolic syndrome; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; CD68 ANTIGEN; CERAMIDE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LACTOSYLCERAMIDE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SERINE PALMITOYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CERVICAL SPINAL CORD INJURY; CHRONIC INFLAMMATION; CHRONIC LIVER DISEASE; CONTROLLED STUDY; EXPERIMENTAL SPINAL CORD CONTUSION; FEMALE; GENE EXPRESSION; HEPATITIS; LIPID LIVER LEVEL; LIPID STORAGE; LIPIDOMICS; LIVER DYSFUNCTION; LIVER INJURY; MACROPHAGE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; RAT MODEL; REVIEW; SPINAL CORD INJURY; THORACIC SPINAL CORD; ANIMAL; COMPLICATION; DISEASE MODEL; LIVER; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; LIVER; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD INJURIES;

EID: 84921534694     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2014.3497     Document Type: Review

References (73)

1. Bao, F., Brown, A., Dekaban, G.A., Omana, V., and Weaver, L.C. (2011). CD11d integrin blockade reduces the systemic inflammatory response syndrome after spinal cord injury. Exp. Neurol. 231, 272-283.
2. Bao, F., Omana, V., Brown, A., and Weaver, L.C. (2012). The systemic inflammatory response after spinal cord injury in the rat is decreased by alpha4beta1 integrin blockade. J. Neurotrauma 29, 1626-1637.
3. Campbell, S.J., Perry, V.H., Pitossi, F.J., Butchart, A.G., Chertoff, M., Waters, S., Dempster, R., and Anthony, D.C. (2005). Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver. Am. J. Pathol. 166, 1487-1497.
4. Campbell, S.J., Zahid, I., Losey, P., Law, S., Jiang, Y., Bilgen, M., van Rooijen, N., Morsali, D., Davis, A.E., and Anthony, D.C. (2008). Liver Kupffer cells control the magnitude of the inflammatory response in the injured brain and spinal cord. Neuropharmacology 55, 780-787.
5. Fleming, J.C., Bailey, C.S., Hundt, H., Gurr, K.R., Bailey, S.I., Cepinskas, G., Lawendy, A.R., and Badhwar, A. (2012). Remote inflammatory response in liver is dependent on the segmental level of spinal cord injury. J. Trauma Acute Care Surg. 72, 1194-1202.
6. Gris, D., Hamilton, E.F., and Weaver, L.C. (2008). The systemic inflammatory response after spinal cord injury damages lungs and kidneys. Exp. Neurol. 211, 259-270.
7. Manns, P.J., McCubbin, J.A., and Williams, D.P. (2005). Fitness, inflammation, and the metabolic syndrome in men with paraplegia. Arch. Phys. Med. Rehabil. 86, 1176-1181.
8. Maruyama, Y., Mizuguchi, M., Yaginuma, T., Kusaka, M., Yoshida, H., Yokoyama, K., Kasahara, Y., and Hosoya, T. (2008). Serum leptin, abdominal obesity and the metabolic syndrome in individuals with chronic spinal cord injury. Spinal Cord 46, 494-499.
9. Nelson, M.D., Widman, L.M., Abresch, R.T., Stanhope, K., Havel, P.J., Styne, D.M., and McDonald, C.M. (2007). Metabolic syndrome in adolescents with spinal cord dysfunction. J. Spinal Cord Med. 30, Suppl 1, S127-S139.
10. Cragg, J.J., Stone, J.A., and Krassioukov, A.V. (2012). Management of cardiovascular disease risk factors in individuals with chronic spinal cord injury: an evidence-based review. J. Neurotrauma 29, 1999-2012.
11. Huang, C.C., Liu, C.W., Weng, M.C., Chen, T.W., and Huang, M.H. (2008). Association of C-reactive protein and insulin resistance in patients with chronic spinal cord injury. J. Rehabil. Med. 40, 819-822.
12. Farrell, G.C., van Rooyen, D., Gan, L., and Chitturi, S. (2012). NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 6, 149-171.
13. Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., Omatsu, T., Nakajima, T., Sarui, H., Shimazaki, M., Kato, T., Okuda, J., and Ida, K. (2005). The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 143, 722-728.
14. Paschos, P., and Paletas, K. (2009). Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13, 9-19.
15. Rosselli, M., Lotersztajn, S., Vizzutti, F., Arena, U., Pinzani, M., and Marra, F. (2014). The metabolic syndrome and chronic liver disease. Curr. Pharm. Des. 20, 5010-5024.
16. Inskip, J., Plunet, W., Ramer, L., Ramsey, J.B., Yung, A., Kozlowski, P., Ramer, M., and Krassioukov, A. (2010). Cardiometabolic risk factors in experimental spinal cord injury. J. Neurotrauma 27, 275-285.
17. Lee, M.Y., Myers, J., Hayes, A., Madan, S., Froelicher, V.F., Perkash, I., and Kiratli, B.J. (2005). C-reactive protein, metabolic syndrome, and insulin resistance in individuals with spinal cord injury. J. Spinal Cord Med. 28, 20-25.
18. Sipski, M.L., Estores, I.M., Alexander, C.J., Guo, X., and Chandralapaty, S.K. (2004). Lack of justification for routine abdominal ultrasonography in patients with chronic spinal cord injury. J. Rehabil. Res. Dev. 41, 101-108.
19. Sanyal, A.J., Yoon, S.K. and Lencioni, R. (2010). The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15, Suppl 4, 14-22.
20. Almad, A., Lash, A.T., Wei, P., Lovett-Racke, A.E., and McTigue, D.M. (2011). The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp. Neurol. 232, 309-317.
21. Almad, A., and McTigue, D.M. (2010). Chronic expression of PPARdelta by oligodendrocyte lineage cells in the injured rat spinal cord. J. Comp. Neurol. 518, 785-799.
22. Sauerbeck, A., Schonberg, D.L., Laws, J.L., and McTigue, D.M. (2013). Systemic iron chelation results in limited functional and histological recovery after traumatic spinal cord injury in rats. Exp. Neurol. 248, 53-61.
23. Bandaru, V.V., Mielke, M.M., Sacktor, N., McArthur, J.C., Grant, I., Letendre, S., Chang, L., Wojna, V., Pardo, C., Calabresi, P., Munsaka, S., and Haughey, N.J. (2013). A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology 81, 1492-1499.
24. Haughey, N.J., Cutler, R.G., Tamara, A., McArthur, J.C., Vargas, D.L., Pardo, C.A., Turchan, J., Nath, A., and Mattson, M.P. (2004). Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann. Neurol. 55, 257-267.
25. Schmittgen, T.D., and Livak, K.J. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101-1108.
26. Suzuki, M., Shinohara, Y., Ohsaki, Y., and Fujimoto, T. (2011). Lipid droplets: size matters. J. Electron Microsc. (Tokyo) 60, Suppl 1, S101-S116.
27. Obeid, L.M., Linardic, C.M., Karolak, L.A., and Hannun, Y.A. (1993). Programmed cell death induced by ceramide. Science 259, 1769-1771.
28. Schiffmann, S., Ferreiros, N., Birod, K., Eberle, M., Schreiber, Y., Pfeilschifter, W., Ziemann, U., Pierre, S., Scholich, K., Grösch, S., and Geisslinger, G. (2012). Ceramide synthase 6 plays a critical role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 188, 5723-5733.
29. Teichgräber, V., Ulrich, M., Endlich, N., Riethmü ller, J., Wilker, B., De Oliveira-Munding, C.C., van Heeckeren, A.M., Barr, M.L., von Kürthy, G., Schmid, K.W., Weller, M., Tümmler, B., Lang, F., Grassme, H., Döring, G., and Gulbins, E. (2008). Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 14, 382-391.
30. Lyn-Cook, L.E., Jr., Lawton, M., Tong, M., Silbermann, E., Longato, L., Jiao, P., Mark, P., Wands, J.R., Xu, H., and de la Monte, S.M. (2009). Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J. Alzheimers Dis. 16, 715-729.
31. Tong, M., and de la Monte, S.M. (2009). Mechanisms of ceramidemediated neurodegeneration. J. Alzheimers Dis. 16, 705-714.
32. Inskip, J.A., Ramer, L.M., Ramer, M.S., Krassioukov, A.V., and Claydon, V.E. (2012). Spectral analyses of cardiovascular control in rodents with spinal cord injury. J. Neurotrauma 29, 1638-1649.
33. Krassioukov, A. (2009). Autonomic function following cervical spinal cord injury. Respir. Physiol. Neurobiol. 169, 157-164.
34. West, C.R., Mills, P., and Krassioukov, A.V. (2012). Influence of the neurological level of spinal cord injury on cardiovascular outcomes in humans: a meta-analysis. Spinal Cord 50, 484-492.
35. Gibson, A.E., Buchholz, A.C., and Martin Ginis, K.A. (2008). CReactive protein in adults with chronic spinal cord injury: increased chronic inflammation in tetraplegia vs paraplegia. Spinal Cord 46, 616-621.
36. Brunt, E.M., and Tiniakos, D.G. (2002). Pathology of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16, 691-707.
37. Farrell, G.C., and Larter, C.Z. (2006). Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-Suppl 1, S99-S112.
38. Charlton, M.R., Burns, J.M., Pedersen, R.A., Watt, K.D., Heimbach, J.K., and Dierkhising, R.A. (2011). Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141, 1249-1253.
39. Imai, K., Kadowaki, T., Aizawa, Y., and Fukutomi, K. (1996). Problems in the health management of persons with spinal cord injury. J. Clin. Epidemiol. 49, 505-510.
40. Bloom, K.K., and Freed, M.M. (1989). Liver enzyme abnormalities in spinal cord injury. J. Am. Paraplegia Soc. 12, 11-13.
41. Trauner, M., Arrese, M., and Wagner, M. (2010). Fatty liver and lipotoxicity. Biochim. Biophys. Acta 1801, 299-310.
42. Bikman, B.T., and Summers, S.A. (2011). Sphingolipids and hepatic steatosis. Adv. Exp. Med. Biol 721, 87-97.
43. Wilcockson, D.C., Campbell, S.J., Anthony, D.C., and Perry, V.H. (2002). The systemic and local acute phase response following acute brain injury. J. Cereb. Blood Flow Metab. 22, 318-326.
44. Pagadala, M., Kasumov, T., McCullough, A.J., Zein, N.N., and Kirwan, J.P. (2012). Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 23, 365-371.
45. Babenko, N.A., and Shakhova, E.G. (2014). Long-term food restriction prevents aging-associated sphingolipid turnover dysregulation in the brain. Arch. Gerontol. Geriatr. 58, 420-426.
46. Babenko, N.A., Hassouneh, L., Kharchenko, V.S., and Garkavenko, V.V. (2012). Vitamin E prevents the age-dependent and palmitateinduced disturbances of sphingolipid turnover in liver cells. Age (Dordr) 34, 905-915.
47. Longato, L., Ripp, K., Setshedi, M., Dostalek, M., Akhlaghi, F., Branda, M., Wands, J.R., and de la Monte, S.M. (2012). Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease. Oxid. Med. Cell Longev. 2012, 479348.
48. Bhargava, P., and Lee, C.H. (2012). Role and function of macrophages in the metabolic syndrome. Biochem. J. 442, 253-262.
49. Sims, K., Haynes, C.A., Kelly, S., Allegood, J.C., Wang, E., Momin, A., Leipelt, M., Reichart, D., Glass, C.K., Sullards, M.C., and Merrill, A.H., Jr. (2010). Kdo2-lipid A, a TLR4-specific agonist, induces de novo sphingolipid biosynthesis in RAW264.7 macrophages, which is essential for induction of autophagy. J. Biol. Chem. 285, 38568-38579.
50. Schilling, J.D., Machkovech, H.M., He, L., Sidhu, R., Fujiwara, H., Weber, K., Ory, D.S., and Schaffer, J.E. (2013). Palmitate and lipopolysaccharide trigger synergistic ceramide production in primary macrophages. J. Biol. Chem. 288, 2923-2932.
51. Wheeler, D., Knapp, E., Bandaru, V.V., Wang, Y., Knorr, D., Poirier, C., Mattson, M.P., Geiger, J.D., and Haughey, N.J. (2009). Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J. Neurochem. 109, 1237-1249.
52. Won, J.S., Singh, A.K. and Singh, I. (2007). Lactosylceramide: a lipid second messenger in neuroinflammatory disease. J. Neurochem. 103, Suppl 1, 180-191.
53. Chatterjee, S., and Pandey, A. (2008). The Yin and Yang of lactosylceramide metabolism: implications in cell function. Biochim. Biophys. Acta 1780, 370-382.
54. Anthony, D.C., Couch, Y., Losey, P., and Evans, M.C. (2012). The systemic response to brain injury and disease. Brain Behav. Immun. 26, 534-540.
55. Prieur, X., Roszer, T., and Ricote, M. (2010). Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim. Biophys. Acta 1801, 327-337.
56. de la Monte, S.M. (2009). Insulin resistance and Alzheimer's disease. BMB Rep. 42, 475-481.
57. de la Monte, S.M., Longato, L., Tong, M., DeNucci, S., and Wands, J.R. (2009). The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int. J. Environ. Res. Public Health 6, 2055-2075.
58. Pruss, H., Kopp, M.A., Brommer, B., Gatzemeier, N., Laginha, I., Dirnagl, U., and Schwab, J.M. (2011). Non-resolving aspects of acute inflammation after spinal cord injury (SCI): indices and resolution plateau. Brain Pathol. 21, 652-660.
59. Wang, T.D., Wang, Y.H., Huang, T.S., Su, T.C., Pan, S.L., and Chen, S.Y. (2007). Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury. J. Formos. Med. Assoc. 106, 919-928.
60. Tosello-Trampont, A.C., Landes, S.G., Nguyen, V., Novobrantseva, T.I., and Hahn, Y.S. (2012). Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J. Biol. Chem. 287, 40161-40172.
61. Bian, Z., Peng, Y., You, Z., Wang, Q., Miao, Q., Liu, Y., Han, X., Qiu, D., Li, Z., and Ma, X. (2013). CCN1 expression in hepatocytes contributes to macrophage infiltration in nonalcoholic fatty liver disease in mice. J. Lipid Res. 54, 44-54.
62. Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., and Seki, E. (2012). Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1310-1321.
63. Bikman, B.T. (2012). A role for sphingolipids in the pathophysiology of obesity-induced inflammation. Cell Mol Life Sci 69, 2135-2146.
64. Nanji, A.A., French, S.W., and Freeman, J.B. (1986). Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 36, 266-269.
65. Ozawa, E., Abiru, S., Nagaoka, S., Yano, K., Komori, A., Migita, K., Yatsuhashi, H., Taura, N., Ichikawa, T., Ishibashi, H., and Nakao, K. (2011). Ferritin/alanine aminotransferase ratio as a possible marker for predicting the prognosis of acute liver injury. J. Gastroenterol. Hepatol. 26, 1326-1332.
66. Lucin, K.M., Sanders, V.M., Jones, T.B., Malarkey, W.B., and Popovich, P.G. (2007). Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation. Exp. Neurol. 207, 75-84.
67. Zhang, Y., Guan, Z., Reader, B., Shawler, T., Mandrekar-Colucci, S., Huang, K., Weil, Z., Bratasz, A., Wells, J., Powell, N.D., Sheridan, J.F., Whitacre, C.C., Rabchevsky, A.G., Nash, M.S., and Popovich, P.G. (2013). Autonomic dysreflexia causes chronic immune suppression after spinal cord injury. J. Neurosci. 33, 12970-12981.
68. Grossman, R.G., Fehlings, M.G., Frankowski, R.F., Burau, K.D., Chow, D.S., Tator, C., Teng, A., Toups, E.G., Harrop, J.S., Aarabi, B., Shaffrey, C.I., Johnson, M.M., Harkema, S.J., Boakye, M., Guest, J.D., and Wilson, J.R. (2014). A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J. Neurotrauma 31, 239-255.
69. Pongratz, D., Neundörfer, B., and Fischer, W. (2000). German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. 180, 82-85.
70. Catania, A., Lonati, C., Sordi, A., and Gatti, S. (2009). Detrimental consequences of brain injury on peripheral cells. Brain Behav. Immun. 23, 877-884.
71. Pratschke, J., Wilhelm, M.J., Kusaka, M., Basker, M., Cooper, D.K., Hancock, W.W. and Tilney, N.L. (1999). Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation 67, 343-348.
72. Zhang, S.J., and Wang, T. (2011). The influence of brain death on donor liver and the potential mechanisms of protective intervention. Front. Med. 5, 8-14.
73. Ben Amor, S., Saied, M.Z., Harzallah, M.S., and Benammou, S. (2013). Hepatic myelopathy with spastic paraparesis: report of two cases and review of the literature. Eur Spine J.